SciSparc Ltd. (SPRC) 10-Year Financial Performance & Capital Metrics

SPRC • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutSciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.Show more

Revenue $1M -54.6%
EBITDA -$7M -30.5%
Net Income -$6M -22.7%
EPS (Diluted) -1.08 +98.5%
Gross Margin 38.74% -49.2%
EBITDA Margin -523.28% -187.8%
Operating Margin -560.18% -179.4%
Net Margin -481.16% -170.5%
ROE -67.84% -6.2%
ROIC -73% +11.6%
Debt/Equity 0.01 -35.1%
Interest Coverage -243.87 +62.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 21.3%
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y21.27%

3Y6.9%

TTM73.22%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-36.09%

EPS CAGR

10Y-

5Y-

3Y-

TTM84.8%

ROCE

10Y Avg-630.39%

5Y Avg-160.06%

3Y Avg-83.92%

Latest-78.84%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	487K	838K	498K	550K	1.07M	1.35M	2.88M	1.31M
Revenue Growth %	-	-	-	0.72%	-0.41%	0.1%	0.94%	0.26%	1.14%	-0.55%
Cost of Goods Sold+	3.09K	0	5K	147K	179K	164K	33K	322K	683K	800K
COGS % of Revenue	-	-	0.01%	0.18%	0.36%	0.3%	0.03%	0.24%	0.24%	0.61%
Gross Profit+	-3.09K	0	482K	691K	319K	386K	1.04M	1.02M	2.2M	506K
Gross Margin %	-	-	0.99%	0.82%	0.64%	0.7%	0.97%	0.76%	0.76%	0.39%
Gross Profit Growth %	-	1%	-	0.43%	-0.54%	0.21%	1.68%	-0.01%	1.14%	-0.77%
Operating Expenses+	2.6M	2.03M	5.75M	9.29M	4.11M	2.55M	5.77M	8.4M	7.97M	7.82M
OpEx % of Revenue	-	-	11.81%	11.08%	8.25%	4.64%	5.4%	6.24%	2.77%	5.99%
Selling, General & Admin	804.12K	1.29M	3.74M	5.81M	2.4M	1.72M	3.64M	6.27M	6.13M	5.8M
SG&A % of Revenue	-	-	7.67%	6.93%	4.81%	3.13%	3.41%	4.65%	2.13%	4.44%
Research & Development	238.49K	738.83K	2.02M	2.71M	1.64M	649K	1.99M	2.8M	1.64M	1.81M
R&D % of Revenue	-	-	4.14%	3.23%	3.29%	1.18%	1.86%	2.08%	0.57%	1.39%
Other Operating Expenses	1.55M	1.56K	0	768K	72K	182K	135K	224K	0	202K
Operating Income+	-2.55M	-2M	-5.75M	-9.71M	-4.11M	-3.29M	-5.77M	-7.38M	-5.77M	-7.32M
Operating Margin %	-	-	-11.82%	-11.59%	-8.25%	-5.99%	-5.4%	-5.48%	-2.01%	-5.6%
Operating Income Growth %	-0.44%	0.22%	-1.88%	-0.69%	0.58%	0.2%	-0.75%	-0.28%	0.22%	-0.27%
EBITDA+	-2.55M	-1.99M	-5.75M	-9.57M	-3.93M	-3.13M	-5.74M	-7.19M	-5.24M	-6.83M
EBITDA Margin %	-	-	-11.8%	-11.42%	-7.89%	-5.69%	-5.36%	-5.34%	-1.82%	-5.23%
EBITDA Growth %	-0.46%	0.22%	-1.88%	-0.66%	0.59%	0.2%	-0.83%	-0.25%	0.27%	-0.31%
D&A (Non-Cash Add-back)	2.82K	3.65K	5K	147K	179K	164K	33K	187K	538K	482K
EBIT	-2.57M	-2.01M	-5.75M	-7.08M	-3.91M	-2.55M	-5.78M	-2.54M	-5.85M	-7.46M
Net Interest Income+	0	-520	-4K	380K	-265K	605K	6K	6.59M	-9K	391K
Interest Income	0	780	1K	503K	303K	630K	18K	1.24M	0	421K
Interest Expense	0	1.3K	5K	123K	568K	25K	12K	36K	9K	30K
Other Income/Expense	-42.27K	-7.94K	-490K	1.22M	-371K	-242K	-21K	4.8M	-88K	-170K
Pretax Income+	-2.61M	-2M	-6.24M	-9.01M	-4.48M	-3.54M	-5.79M	-2.58M	-5.86M	-7.49M
Pretax Margin %	-	-	-12.82%	-10.75%	-8.99%	-6.43%	-5.42%	-1.91%	-2.04%	-5.73%
Income Tax+	-21.77K	-6.76K	0	-60K	0	0	0	14K	22K	-14K
Effective Tax Rate %	0.97%	0.99%	1%	0.95%	1.2%	0.99%	1%	1.01%	0.87%	0.84%
Net Income+	-2.53M	-1.99M	-6.24M	-8.52M	-5.36M	-3.51M	-5.8M	-2.59M	-5.12M	-6.28M
Net Margin %	-	-	-12.82%	-10.17%	-10.77%	-6.38%	-5.43%	-1.92%	-1.78%	-4.81%
Net Income Growth %	-0.37%	0.21%	-2.14%	-0.36%	0.37%	0.35%	-0.65%	0.55%	-0.98%	-0.23%
Net Income (Continuing)	-2.57M	-2.01M	-6.24M	-6.53M	-4.48M	-3.54M	-5.79M	-2.59M	-5.88M	-7.47M
Discontinued Operations	-10.81K	0	0	-2.42M	-315K	0	0	0	0	0
Minority Interest	-155.5K	0	261K	-108K	0	0	0	0	1.97M	785K
EPS (Diluted)+	0.00	0.00	0.00	0.00	0.00	0.00	-367.90	-74.10	-72.15	-1.08
EPS Growth %	-	-	-	-	-	-	-	0.8%	0.03%	0.99%
EPS (Basic)	0.00	0.00	0.00	0.00	0.00	0.00	-73.28	-14.73	-12.55	-1.08
Diluted Shares Outstanding	0	0	0	0	0	0	790K	880K	2.04M	5.82M
Basic Shares Outstanding	0	0	0	0	0	0	786.76K	874.49K	1.77M	5.82M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.65M	803.83K	9.5M	2.43M	955K	2.55M	9.82M	4.51M	6.45M	7.5M
Cash & Short-Term Investments	1.57M	675.4K	9.2M	1.49M	870K	1.95M	6.88M	3.57M	5.08M	2.06M
Cash Only	1.57M	675.4K	9.2M	1.49M	870K	1.95M	6.88M	3.57M	2.08M	1.54M
Short-Term Investments	0	0	0	0	0	0	0	0	3M	517K
Accounts Receivable	33.92K	108K	54K	685K	64K	286K	2.56M	168K	287K	4.96M
Days Sales Outstanding	-	-	40.47	298.36	46.91	189.8	872.72	45.52	36.39	1.39K
Inventory	0	0	0	-271K	10K	10K	45K	668K	742K	113K
Days Inventory Outstanding	-	-	-	-	20.39	22.26	497.73	757.21	396.53	51.56
Other Current Assets	11.27K	11K	24K	10K	10K	10K	45K	60K	65K	20K
Total Non-Current Assets+	10.76K	440.91K	69K	2.13M	199K	11K	92K	6.09M	4.74M	2.84M
Property, Plant & Equipment	10.76K	11.44K	50K	2.11M	175K	11K	92K	57K	108K	59K
Fixed Asset Turnover	-	-	9.74x	0.40x	2.85x	50.00x	11.62x	23.63x	26.66x	22.14x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	4.72M	3.19M	1.48M
Long-Term Investments	0	0	0	23K	24K	0	0	1.32M	1.44M	1.31M
Other Non-Current Assets	0	429.47K	19K	0	0	-11K	-92K	-6.09M	0	0
Total Assets+	1.67M	1.24M	9.57M	4.56M	1.15M	2.56M	9.92M	10.61M	11.18M	10.35M
Asset Turnover	-	-	0.05x	0.18x	0.43x	0.21x	0.11x	0.13x	0.26x	0.13x
Asset Growth %	5.38%	-0.25%	6.69%	-0.52%	-0.75%	1.22%	2.87%	0.07%	0.05%	-0.07%
Total Current Liabilities+	510.8K	672.02K	1.18M	4.48M	1.05M	1.13M	1.76M	4.16M	1.57M	1.4M
Accounts Payable	110.92K	80K	399K	978K	339K	277K	441K	298K	264K	816K
Days Payables Outstanding	13.11K	-	29.13K	2.43K	691.26	616.49	4.88K	337.8	141.08	372.3
Short-Term Debt	0	0	0	1.15M	406K	188K	441K	0	0	0
Deferred Revenue (Current)	0	0	0	1000K	294K	-277K	-154K	0	0	0
Other Current Liabilities	33.81K	22	0	1.82M	-332K	632K	-769K	2.81M	636K	471K
Current Ratio	3.24x	1.20x	8.07x	0.54x	0.91x	2.25x	5.59x	1.09x	4.10x	5.36x
Quick Ratio	3.24x	1.20x	8.07x	0.60x	0.90x	2.25x	5.57x	0.92x	3.63x	5.28x
Cash Conversion Cycle	-	-	-	-	-623.96	-404.44	-3.51K	464.93	291.83	1.07K
Total Non-Current Liabilities+	110.92K	79.81K	399K	2.83M	94K	0	18K	1.23M	24K	9K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	94K	0	18K	0	24K	9K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	510.8K	672.02K	1.18M	4.48M	1.14M	1.13M	1.77M	4.16M	1.59M	1.41M
Total Debt+	0	0	0	1.85M	500K	465K	504K	27K	76K	46K
Net Debt	-1.57M	-675.4K	-9.2M	363K	-370K	-1.48M	-6.37M	-3.55M	-2M	-1.49M
Debt / Equity	-	-	-	24.00x	35.71x	0.33x	0.06x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-1536.40x	-1150.80x	-78.98x	-7.23x	-131.72x	-480.67x	-205.00x	-641.44x	-243.87x
Total Equity+	1.15M	572.71K	8.39M	77K	14K	1.43M	8.14M	6.45M	9.59M	8.94M
Equity Growth %	10.92%	-0.5%	13.65%	-0.99%	-0.82%	101.14%	4.69%	-0.21%	0.49%	-0.07%
Book Value per Share	-	-	-	-	-	-	10.31	7.33	4.70	1.53
Total Shareholders' Equity	1.31M	572.71K	8.13M	185K	14K	1.43M	8.14M	6.45M	7.61M	8.15M
Common Stock	906.84K	1.07M	3.81M	3.82M	6.32M	49.04M	58.54M	58.59M	64.53M	70.89M
Retained Earnings	-29.07M	-31.49M	-38.39M	-46.91M	-51.71M	-55.19M	-60.98M	-63.57M	-68.69M	-74.97M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	4.94M	4.63M	6.09M	497K	497K	497K	497K	497K	11.78M	497K
Minority Interest	-155.5K	0	261K	-108K	0	0	0	0	1.97M	785K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.32M	-1.48M	-4.58M	-7.13M	-4.7M	-4.31M	-5.06M	-7.92M	-5.89M	-5.1M
Operating CF Margin %	-	-	-9.4%	-8.51%	-9.43%	-7.83%	-4.73%	-5.88%	-2.04%	-3.91%
Operating CF Growth %	0.3%	-0.12%	-2.1%	-0.56%	0.34%	0.08%	-0.18%	-0.56%	0.26%	0.13%
Net Income	-2.61M	-2M	-6.24M	-8.95M	-4.69M	-3.54M	-5.79M	-2.59M	-5.12M	-7.47M
Depreciation & Amortization	2.82K	3.64K	5K	147K	179K	164K	33K	187K	538K	482K
Stock-Based Compensation	1.14M	326.52K	862K	604K	553K	91K	43K	897K	196K	569K
Deferred Taxes	6.4K	-33.8K	1K	-60K	1.22M	795K	0	0	0	0
Other Non-Cash Items	8.97K	-5.2K	525K	-269K	156K	-476K	9K	-5.71M	-666K	1.18M
Working Capital Changes	128.85K	233.45K	272K	1.4M	-2.12M	-1.35M	643K	-703K	-833K	136K
Change in Receivables	-45.34K	-109.45K	-143K	-99K	329K	-519K	170K	-77K	-354K	-523K
Change in Inventory	0	0	0	649K	-329K	519K	-170K	-668K	-74K	629K
Change in Payables	152.93K	232.15K	349K	177K	-840K	-752K	353K	0	-397K	25K
Cash from Investing+	-512	-4.42K	-53K	-2.09M	1.27M	24K	-70K	-7.08M	-1.11M	-1.63M
Capital Expenditures	-1.02K	-4.16K	-44K	-17K	-1K	0	-35K	-4.87M	0	0
CapEx % of Revenue	-	-	0.09%	0.02%	0%	-	0.03%	3.61%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2	261	-11K	-2.09M	1.27M	24K	-35K	-15K	-5K	-4.03M
Cash from Financing+	2.74M	563.87K	13.18M	1.54M	2.8M	5.36M	10.06M	11.7M	5.5M	6.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.3M	565K	-18K	-36K	635K	2.48M	0	2.77M	-7K	-8K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.32M	-1.48M	-4.62M	-7.15M	-4.7M	-4.31M	-5.1M	-12.79M	-5.89M	-5.1M
FCF Margin %	-	-	-9.49%	-8.53%	-9.43%	-7.83%	-4.77%	-9.49%	-2.04%	-3.91%
FCF Growth %	0.3%	-0.12%	-2.12%	-0.55%	0.34%	0.08%	-0.18%	-1.51%	0.54%	0.13%
FCF per Share	-	-	-	-	-	-	-6.45	-14.53	-2.89	-0.88
FCF Conversion (FCF/Net Income)	0.52x	0.74x	0.73x	0.84x	0.88x	1.23x	0.87x	3.05x	1.15x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-487.41%	-230.46%	-139.35%	-201.35%	-11784.62%	-485.73%	-121.22%	-35.53%	-63.88%	-67.84%
Return on Invested Capital (ROIC)	-	-	-	-1655.8%	-7335.71%	-	-503.32%	-236.94%	-82.56%	-73%
Gross Margin	-	-	98.97%	82.46%	64.06%	70.18%	96.91%	76.09%	76.28%	38.74%
Net Margin	-	-	-1282.14%	-1017.06%	-1076.71%	-637.64%	-542.66%	-192.43%	-177.91%	-481.16%
Debt / Equity	-	-	-	24.00x	35.71x	0.33x	0.06x	0.00x	0.01x	0.01x
Interest Coverage	-	-1536.40x	-1150.80x	-78.98x	-7.23x	-131.72x	-480.67x	-205.00x	-641.44x	-243.87x
FCF Conversion	0.52x	0.74x	0.73x	0.84x	0.88x	1.23x	0.87x	3.05x	1.15x	0.81x
Revenue Growth	-	-	-	72.07%	-40.57%	10.44%	94.36%	26.01%	113.73%	-54.64%

Frequently Asked Questions

Growth & Financials

SciSparc Ltd. (SPRC) reported $4.2M in revenue for fiscal year 2024.

SciSparc Ltd. (SPRC) saw revenue decline by 54.6% over the past year.

SciSparc Ltd. (SPRC) reported a net loss of $11.4M for fiscal year 2024.

Dividend & Returns

SciSparc Ltd. (SPRC) has a return on equity (ROE) of -67.8%. Negative ROE indicates the company is unprofitable.

SciSparc Ltd. (SPRC) had negative free cash flow of $11.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

SciSparc Ltd. (SPRC) 10-Year Financial Performance & Capital Metrics

SPRC • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $1M -54.6%
EBITDA -$7M -30.5%
Net Income -$6M -22.7%
EPS (Diluted) -1.08 +98.5%
Gross Margin 38.74% -49.2%
EBITDA Margin -523.28% -187.8%
Operating Margin -560.18% -179.4%
Net Margin -481.16% -170.5%
ROE -67.84% -6.2%
ROIC -73% +11.6%
Debt/Equity 0.01 -35.1%
Interest Coverage -243.87 +62.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 21.3%
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y21.27%

3Y6.9%

TTM73.22%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-36.09%

EPS CAGR

10Y-

5Y-

3Y-

TTM84.8%

ROCE

10Y Avg-630.39%

5Y Avg-160.06%

3Y Avg-83.92%

Latest-78.84%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	487K	838K	498K	550K	1.07M	1.35M	2.88M	1.31M
Revenue Growth %	-	-	-	0.72%	-0.41%	0.1%	0.94%	0.26%	1.14%	-0.55%
Cost of Goods Sold+	3.09K	0	5K	147K	179K	164K	33K	322K	683K	800K
COGS % of Revenue	-	-	0.01%	0.18%	0.36%	0.3%	0.03%	0.24%	0.24%	0.61%
Gross Profit+	-3.09K	0	482K	691K	319K	386K	1.04M	1.02M	2.2M	506K
Gross Margin %	-	-	0.99%	0.82%	0.64%	0.7%	0.97%	0.76%	0.76%	0.39%
Gross Profit Growth %	-	1%	-	0.43%	-0.54%	0.21%	1.68%	-0.01%	1.14%	-0.77%
Operating Expenses+	2.6M	2.03M	5.75M	9.29M	4.11M	2.55M	5.77M	8.4M	7.97M	7.82M
OpEx % of Revenue	-	-	11.81%	11.08%	8.25%	4.64%	5.4%	6.24%	2.77%	5.99%
Selling, General & Admin	804.12K	1.29M	3.74M	5.81M	2.4M	1.72M	3.64M	6.27M	6.13M	5.8M
SG&A % of Revenue	-	-	7.67%	6.93%	4.81%	3.13%	3.41%	4.65%	2.13%	4.44%
Research & Development	238.49K	738.83K	2.02M	2.71M	1.64M	649K	1.99M	2.8M	1.64M	1.81M
R&D % of Revenue	-	-	4.14%	3.23%	3.29%	1.18%	1.86%	2.08%	0.57%	1.39%
Other Operating Expenses	1.55M	1.56K	0	768K	72K	182K	135K	224K	0	202K
Operating Income+	-2.55M	-2M	-5.75M	-9.71M	-4.11M	-3.29M	-5.77M	-7.38M	-5.77M	-7.32M
Operating Margin %	-	-	-11.82%	-11.59%	-8.25%	-5.99%	-5.4%	-5.48%	-2.01%	-5.6%
Operating Income Growth %	-0.44%	0.22%	-1.88%	-0.69%	0.58%	0.2%	-0.75%	-0.28%	0.22%	-0.27%
EBITDA+	-2.55M	-1.99M	-5.75M	-9.57M	-3.93M	-3.13M	-5.74M	-7.19M	-5.24M	-6.83M
EBITDA Margin %	-	-	-11.8%	-11.42%	-7.89%	-5.69%	-5.36%	-5.34%	-1.82%	-5.23%
EBITDA Growth %	-0.46%	0.22%	-1.88%	-0.66%	0.59%	0.2%	-0.83%	-0.25%	0.27%	-0.31%
D&A (Non-Cash Add-back)	2.82K	3.65K	5K	147K	179K	164K	33K	187K	538K	482K
EBIT	-2.57M	-2.01M	-5.75M	-7.08M	-3.91M	-2.55M	-5.78M	-2.54M	-5.85M	-7.46M
Net Interest Income+	0	-520	-4K	380K	-265K	605K	6K	6.59M	-9K	391K
Interest Income	0	780	1K	503K	303K	630K	18K	1.24M	0	421K
Interest Expense	0	1.3K	5K	123K	568K	25K	12K	36K	9K	30K
Other Income/Expense	-42.27K	-7.94K	-490K	1.22M	-371K	-242K	-21K	4.8M	-88K	-170K
Pretax Income+	-2.61M	-2M	-6.24M	-9.01M	-4.48M	-3.54M	-5.79M	-2.58M	-5.86M	-7.49M
Pretax Margin %	-	-	-12.82%	-10.75%	-8.99%	-6.43%	-5.42%	-1.91%	-2.04%	-5.73%
Income Tax+	-21.77K	-6.76K	0	-60K	0	0	0	14K	22K	-14K
Effective Tax Rate %	0.97%	0.99%	1%	0.95%	1.2%	0.99%	1%	1.01%	0.87%	0.84%
Net Income+	-2.53M	-1.99M	-6.24M	-8.52M	-5.36M	-3.51M	-5.8M	-2.59M	-5.12M	-6.28M
Net Margin %	-	-	-12.82%	-10.17%	-10.77%	-6.38%	-5.43%	-1.92%	-1.78%	-4.81%
Net Income Growth %	-0.37%	0.21%	-2.14%	-0.36%	0.37%	0.35%	-0.65%	0.55%	-0.98%	-0.23%
Net Income (Continuing)	-2.57M	-2.01M	-6.24M	-6.53M	-4.48M	-3.54M	-5.79M	-2.59M	-5.88M	-7.47M
Discontinued Operations	-10.81K	0	0	-2.42M	-315K	0	0	0	0	0
Minority Interest	-155.5K	0	261K	-108K	0	0	0	0	1.97M	785K
EPS (Diluted)+	0.00	0.00	0.00	0.00	0.00	0.00	-367.90	-74.10	-72.15	-1.08
EPS Growth %	-	-	-	-	-	-	-	0.8%	0.03%	0.99%
EPS (Basic)	0.00	0.00	0.00	0.00	0.00	0.00	-73.28	-14.73	-12.55	-1.08
Diluted Shares Outstanding	0	0	0	0	0	0	790K	880K	2.04M	5.82M
Basic Shares Outstanding	0	0	0	0	0	0	786.76K	874.49K	1.77M	5.82M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.65M	803.83K	9.5M	2.43M	955K	2.55M	9.82M	4.51M	6.45M	7.5M
Cash & Short-Term Investments	1.57M	675.4K	9.2M	1.49M	870K	1.95M	6.88M	3.57M	5.08M	2.06M
Cash Only	1.57M	675.4K	9.2M	1.49M	870K	1.95M	6.88M	3.57M	2.08M	1.54M
Short-Term Investments	0	0	0	0	0	0	0	0	3M	517K
Accounts Receivable	33.92K	108K	54K	685K	64K	286K	2.56M	168K	287K	4.96M
Days Sales Outstanding	-	-	40.47	298.36	46.91	189.8	872.72	45.52	36.39	1.39K
Inventory	0	0	0	-271K	10K	10K	45K	668K	742K	113K
Days Inventory Outstanding	-	-	-	-	20.39	22.26	497.73	757.21	396.53	51.56
Other Current Assets	11.27K	11K	24K	10K	10K	10K	45K	60K	65K	20K
Total Non-Current Assets+	10.76K	440.91K	69K	2.13M	199K	11K	92K	6.09M	4.74M	2.84M
Property, Plant & Equipment	10.76K	11.44K	50K	2.11M	175K	11K	92K	57K	108K	59K
Fixed Asset Turnover	-	-	9.74x	0.40x	2.85x	50.00x	11.62x	23.63x	26.66x	22.14x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	4.72M	3.19M	1.48M
Long-Term Investments	0	0	0	23K	24K	0	0	1.32M	1.44M	1.31M
Other Non-Current Assets	0	429.47K	19K	0	0	-11K	-92K	-6.09M	0	0
Total Assets+	1.67M	1.24M	9.57M	4.56M	1.15M	2.56M	9.92M	10.61M	11.18M	10.35M
Asset Turnover	-	-	0.05x	0.18x	0.43x	0.21x	0.11x	0.13x	0.26x	0.13x
Asset Growth %	5.38%	-0.25%	6.69%	-0.52%	-0.75%	1.22%	2.87%	0.07%	0.05%	-0.07%
Total Current Liabilities+	510.8K	672.02K	1.18M	4.48M	1.05M	1.13M	1.76M	4.16M	1.57M	1.4M
Accounts Payable	110.92K	80K	399K	978K	339K	277K	441K	298K	264K	816K
Days Payables Outstanding	13.11K	-	29.13K	2.43K	691.26	616.49	4.88K	337.8	141.08	372.3
Short-Term Debt	0	0	0	1.15M	406K	188K	441K	0	0	0
Deferred Revenue (Current)	0	0	0	1000K	294K	-277K	-154K	0	0	0
Other Current Liabilities	33.81K	22	0	1.82M	-332K	632K	-769K	2.81M	636K	471K
Current Ratio	3.24x	1.20x	8.07x	0.54x	0.91x	2.25x	5.59x	1.09x	4.10x	5.36x
Quick Ratio	3.24x	1.20x	8.07x	0.60x	0.90x	2.25x	5.57x	0.92x	3.63x	5.28x
Cash Conversion Cycle	-	-	-	-	-623.96	-404.44	-3.51K	464.93	291.83	1.07K
Total Non-Current Liabilities+	110.92K	79.81K	399K	2.83M	94K	0	18K	1.23M	24K	9K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	94K	0	18K	0	24K	9K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	510.8K	672.02K	1.18M	4.48M	1.14M	1.13M	1.77M	4.16M	1.59M	1.41M
Total Debt+	0	0	0	1.85M	500K	465K	504K	27K	76K	46K
Net Debt	-1.57M	-675.4K	-9.2M	363K	-370K	-1.48M	-6.37M	-3.55M	-2M	-1.49M
Debt / Equity	-	-	-	24.00x	35.71x	0.33x	0.06x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-1536.40x	-1150.80x	-78.98x	-7.23x	-131.72x	-480.67x	-205.00x	-641.44x	-243.87x
Total Equity+	1.15M	572.71K	8.39M	77K	14K	1.43M	8.14M	6.45M	9.59M	8.94M
Equity Growth %	10.92%	-0.5%	13.65%	-0.99%	-0.82%	101.14%	4.69%	-0.21%	0.49%	-0.07%
Book Value per Share	-	-	-	-	-	-	10.31	7.33	4.70	1.53
Total Shareholders' Equity	1.31M	572.71K	8.13M	185K	14K	1.43M	8.14M	6.45M	7.61M	8.15M
Common Stock	906.84K	1.07M	3.81M	3.82M	6.32M	49.04M	58.54M	58.59M	64.53M	70.89M
Retained Earnings	-29.07M	-31.49M	-38.39M	-46.91M	-51.71M	-55.19M	-60.98M	-63.57M	-68.69M	-74.97M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	4.94M	4.63M	6.09M	497K	497K	497K	497K	497K	11.78M	497K
Minority Interest	-155.5K	0	261K	-108K	0	0	0	0	1.97M	785K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.32M	-1.48M	-4.58M	-7.13M	-4.7M	-4.31M	-5.06M	-7.92M	-5.89M	-5.1M
Operating CF Margin %	-	-	-9.4%	-8.51%	-9.43%	-7.83%	-4.73%	-5.88%	-2.04%	-3.91%
Operating CF Growth %	0.3%	-0.12%	-2.1%	-0.56%	0.34%	0.08%	-0.18%	-0.56%	0.26%	0.13%
Net Income	-2.61M	-2M	-6.24M	-8.95M	-4.69M	-3.54M	-5.79M	-2.59M	-5.12M	-7.47M
Depreciation & Amortization	2.82K	3.64K	5K	147K	179K	164K	33K	187K	538K	482K
Stock-Based Compensation	1.14M	326.52K	862K	604K	553K	91K	43K	897K	196K	569K
Deferred Taxes	6.4K	-33.8K	1K	-60K	1.22M	795K	0	0	0	0
Other Non-Cash Items	8.97K	-5.2K	525K	-269K	156K	-476K	9K	-5.71M	-666K	1.18M
Working Capital Changes	128.85K	233.45K	272K	1.4M	-2.12M	-1.35M	643K	-703K	-833K	136K
Change in Receivables	-45.34K	-109.45K	-143K	-99K	329K	-519K	170K	-77K	-354K	-523K
Change in Inventory	0	0	0	649K	-329K	519K	-170K	-668K	-74K	629K
Change in Payables	152.93K	232.15K	349K	177K	-840K	-752K	353K	0	-397K	25K
Cash from Investing+	-512	-4.42K	-53K	-2.09M	1.27M	24K	-70K	-7.08M	-1.11M	-1.63M
Capital Expenditures	-1.02K	-4.16K	-44K	-17K	-1K	0	-35K	-4.87M	0	0
CapEx % of Revenue	-	-	0.09%	0.02%	0%	-	0.03%	3.61%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2	261	-11K	-2.09M	1.27M	24K	-35K	-15K	-5K	-4.03M
Cash from Financing+	2.74M	563.87K	13.18M	1.54M	2.8M	5.36M	10.06M	11.7M	5.5M	6.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.3M	565K	-18K	-36K	635K	2.48M	0	2.77M	-7K	-8K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.32M	-1.48M	-4.62M	-7.15M	-4.7M	-4.31M	-5.1M	-12.79M	-5.89M	-5.1M
FCF Margin %	-	-	-9.49%	-8.53%	-9.43%	-7.83%	-4.77%	-9.49%	-2.04%	-3.91%
FCF Growth %	0.3%	-0.12%	-2.12%	-0.55%	0.34%	0.08%	-0.18%	-1.51%	0.54%	0.13%
FCF per Share	-	-	-	-	-	-	-6.45	-14.53	-2.89	-0.88
FCF Conversion (FCF/Net Income)	0.52x	0.74x	0.73x	0.84x	0.88x	1.23x	0.87x	3.05x	1.15x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-487.41%	-230.46%	-139.35%	-201.35%	-11784.62%	-485.73%	-121.22%	-35.53%	-63.88%	-67.84%
Return on Invested Capital (ROIC)	-	-	-	-1655.8%	-7335.71%	-	-503.32%	-236.94%	-82.56%	-73%
Gross Margin	-	-	98.97%	82.46%	64.06%	70.18%	96.91%	76.09%	76.28%	38.74%
Net Margin	-	-	-1282.14%	-1017.06%	-1076.71%	-637.64%	-542.66%	-192.43%	-177.91%	-481.16%
Debt / Equity	-	-	-	24.00x	35.71x	0.33x	0.06x	0.00x	0.01x	0.01x
Interest Coverage	-	-1536.40x	-1150.80x	-78.98x	-7.23x	-131.72x	-480.67x	-205.00x	-641.44x	-243.87x
FCF Conversion	0.52x	0.74x	0.73x	0.84x	0.88x	1.23x	0.87x	3.05x	1.15x	0.81x
Revenue Growth	-	-	-	72.07%	-40.57%	10.44%	94.36%	26.01%	113.73%	-54.64%

Frequently Asked Questions

Growth & Financials

SciSparc Ltd. (SPRC) reported $4.2M in revenue for fiscal year 2024.

SciSparc Ltd. (SPRC) saw revenue decline by 54.6% over the past year.

SciSparc Ltd. (SPRC) reported a net loss of $11.4M for fiscal year 2024.

Dividend & Returns

SciSparc Ltd. (SPRC) has a return on equity (ROE) of -67.8%. Negative ROE indicates the company is unprofitable.

SciSparc Ltd. (SPRC) had negative free cash flow of $11.0M in fiscal year 2024, likely due to heavy capital investments.